Clinical trial
Efficacy and Safety of BAL4079 in the Treatment of Severe Refractory Chronic Hand Dermatitis
NCT00124475 is registered in ClinicalTrials.gov with Basilea Pharmaceutica as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy and Safety of BAL4079 in the Treatment of Severe Refractory Chronic Hand Dermatitis
- Lead sponsor
- Basilea Pharmaceutica
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- December 31, 2004
- Completion date
- September 30, 2007
- Enrollment
- 1,035
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.